VNUE, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that VNUE, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $529.4K | Apr 15, 2024 |
| FY2023 | Dec 31, 2022 | $359.1K | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | $100.5K | Apr 17, 2023 |
| FY2019 | Dec 31, 2019 | $206.2K | Jun 3, 2020 |
| FY2019 | Dec 31, 2018 | $82.9K | Jun 3, 2020 |
| FY2018 | Dec 31, 2017 | $37.8K | Apr 16, 2019 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $182.6K | Apr 15, 2024 |
| FY2023 | Dec 31, 2022 | $33.3K | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | ($52.7K) | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $14.0K | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | ($4.9K) | Apr 8, 2021 |
| FY2016 | Dec 31, 2016 | $2.54M | Apr 14, 2017 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | ($1.14M) | Apr 15, 2024 |
| FY2023 | Dec 31, 2022 | ($22.76M) | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | $2.92M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | ($4.55M) | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | ($1.40M) | Apr 8, 2021 |
| FY2019 | Dec 31, 2018 | ($2.36M) | Jun 3, 2020 |
| FY2018 | Dec 31, 2017 | ($1.19M) | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | ($2.60M) | Apr 16, 2018 |
| FY2016 | Dec 31, 2015 | ($4.27M) | Apr 14, 2017 |
| FY2015 | Dec 31, 2014 | ($386.7K) | Dec 15, 2016 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | ($1.41M) | Apr 15, 2024 |
| FY2023 | Dec 31, 2022 | ($21.82M) | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | ($984.8K) | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | ($587.1K) | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | ($1.33M) | Apr 8, 2021 |
| FY2019 | Dec 31, 2018 | ($1.20M) | Jun 3, 2020 |
| FY2018 | Dec 31, 2017 | ($1.01M) | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | ($2.37M) | Apr 16, 2018 |
| FY2016 | Dec 31, 2015 | ($4.05M) | Apr 14, 2017 |
| FY2015 | Dec 31, 2014 | ($256.3K) | Dec 15, 2016 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $0 | Apr 8, 2021 |
| FY2020 | Dec 31, 2019 | $12.4K | Apr 8, 2021 |
| FY2019 | Dec 31, 2018 | $12.4K | Jun 3, 2020 |
| FY2018 | Dec 31, 2017 | $118.9K | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | $1.11M | Apr 16, 2018 |
| FY2016 | Dec 31, 2015 | $550.3K | Apr 14, 2017 |
| FY2015 | Dec 31, 2014 | $97.5K | Dec 15, 2016 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | ($1.08M) | Apr 15, 2024 |
| FY2023 | Dec 31, 2022 | ($1.28M) | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | ($1.43M) | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | ($518.5K) | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | ($501.9K) | Apr 8, 2021 |
| FY2019 | Dec 31, 2018 | ($575.8K) | Jun 3, 2020 |
| FY2018 | Dec 31, 2017 | ($437.7K) | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | ($314.3K) | Apr 16, 2018 |
| FY2016 | Dec 31, 2015 | ($828.2K) | Apr 14, 2017 |
| FY2015 | Dec 31, 2014 | ($132.7K) | Dec 15, 2016 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2014 | May 31, 2014 | $0 | Sep 15, 2014 |
| FY2014 | May 31, 2013 | $1.3K | Sep 15, 2014 |
| FY2013 | May 31, 2012 | $1.9K | Sep 16, 2013 |
| FY2012 | May 31, 2011 | $0 | Sep 13, 2012 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $25.4K | Apr 15, 2024 |
| FY2023 | Dec 31, 2022 | $221.9K | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | $501.3K | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $104.5K | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $52.1K | Apr 8, 2021 |
| FY2019 | Dec 31, 2018 | $252.3K | Jun 3, 2020 |
| FY2018 | Dec 31, 2017 | $331.8K | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | $18.0K | Apr 16, 2018 |
| FY2016 | Dec 31, 2015 | $45.3K | Apr 14, 2017 |
| FY2015 | Dec 31, 2014 | $336.3K | Dec 15, 2016 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $6.61M | Apr 15, 2024 |
| FY2023 | Dec 31, 2022 | $6.68M | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | $3.29M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $8.35M | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $3.83M | Apr 8, 2021 |
| FY2019 | Dec 31, 2018 | $4.31M | Jun 3, 2020 |
| FY2018 | Dec 31, 2017 | $3.08M | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | $1.93M | Apr 16, 2018 |
| FY2015 | Dec 31, 2015 | $767.0K | Dec 15, 2016 |
| FY2015 | Dec 31, 2014 | $419.1K | Dec 15, 2016 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | ($6.58M) | Apr 15, 2024 |
| FY2023 | Dec 31, 2022 | ($6.46M) | Apr 15, 2024 |
| FY2023 | Dec 31, 2021 | ($2.79M) | Apr 15, 2024 |
| FY2022 | Dec 31, 2020 | ($8.25M) | Apr 17, 2023 |
| FY2021 | Dec 31, 2019 | ($4.03M) | Apr 15, 2022 |
| FY2020 | Dec 31, 2018 | ($4.05M) | Apr 8, 2021 |
| FY2019 | Dec 31, 2017 | ($2.75M) | Jun 3, 2020 |
| FY2018 | Dec 31, 2016 | ($1.91M) | Apr 16, 2019 |
| FY2017 | Dec 31, 2015 | ($721.7K) | Apr 16, 2018 |
| FY2016 | Dec 31, 2014 | ($82.7K) | Apr 14, 2017 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | ($38.23M) | Apr 15, 2024 |
| FY2023 | Dec 31, 2022 | ($36.81M) | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | ($13.84M) | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | ($16.76M) | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | ($12.20M) | Apr 8, 2021 |
| FY2019 | Dec 31, 2018 | ($10.80M) | Jun 3, 2020 |
| FY2018 | Dec 31, 2017 | ($8.45M) | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | ($7.25M) | Apr 16, 2018 |
| FY2016 | Dec 31, 2015 | ($4.65M) | Apr 14, 2017 |
| FY2015 | Dec 31, 2014 | ($386.7K) | Dec 15, 2016 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $25.4K | Apr 15, 2024 |
| FY2023 | Dec 31, 2022 | $82.8K | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | $37.0K | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $4.5K | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $52.1K | Apr 8, 2021 |
| FY2020 | Dec 31, 2018 | $18.2K | Apr 8, 2021 |
| FY2019 | Dec 31, 2017 | $10.3K | Jun 3, 2020 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | 0 | Apr 15, 2024 |
| FY2023 | Dec 31, 2022 | 0 | Apr 15, 2024 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | 0 | Apr 15, 2024 |
| FY2023 | Dec 31, 2022 | 0 | Apr 15, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | 2.65B | Apr 15, 2024 |
| FY2023 | Dec 31, 2022 | 1.68B | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | 1.41B | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | 1.21B | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | 770.88M | Apr 8, 2021 |
| FY2019 | Dec 31, 2018 | 105.64M | Jun 3, 2020 |
| FY2018 | Dec 31, 2017 | 74.34M | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | 64.49M | Apr 16, 2018 |
| FY2016 | Dec 31, 2015 | 640.91M | Apr 14, 2017 |
| FY2015 | Dec 31, 2014 | 402.48M | Dec 15, 2016 |